Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized controlled study of polyunsaturated fatty acids (Omacor) in schizophrenia
2008-008517-19Phase 4Active
- Sponsor
- Consorci Sanitari del Maresme
- Start
- Mar 2009
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of omega-3-acid triglycerides in schizophrenia and cardiometabolic risk (CMR) (2 arms), sponsored by Consorci Sanitari del Maresme. Primary endpoints: Intensity of schizophrenia symptoms, Global functioning and 2 more. Started Mar 2009; status: active.
02
Drugs
omega-3-acid triglycerides
03
Conditions
schizophreniacardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2008-008517-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008517-19.